Potency of Anlotinib for Inhibition of the KIT and KIT Signaling Pathways In Vitro
MUTANTS, SECONDARY, GIST
We constructed 4 common secondary mutations to evaluate the efficacy of anlotinib against KIT mutants in HEK293T transient transfection model. As shown in Drug sensitivity of KIT mutations.The efficacy of anlotinib against 4 common KIT secondary mutations in HEK293T transient transfection model.To provide more evidence about anlotinib efficacy, we assessed the potency of anlotinib against KIT and KIT signaling pathways in GIST cell lines. In accordance with the above results, anlotinib was capable of slightly inhibiting KIT and KIT signaling pathways in GIST430/654 with an ICThe potency of anlotinib against KIT and KIT signaling pathways in GIST430/654 and GIST48 cell lines.